Bioxodes announces the completion of the active phase of its First-in-Human study performed in healthy adult volunteers with Ir-CPI, a drug candidate for the prevention of thrombosis
Marche-en-Famenne, Belgium, April 29th, 2021 – Bioxodes, a clinical stage biotechnology company announces today the completion of the active phase of its First-in-Human (FIH) study with Ir-CPI dedicated to the prevention of thrombosis. This FIH was a double blind, placebo controlled, single ascending dose trial performed in healthy adult male volunteers with Ir-CPI.
Read the full Press Release here.
Bioxodes obtains authorization to launch phase I trial of its antithrombotic drug, Ir-CPI, in healthy male volunteers
Ir-CPI is a potential best-in-class antithrombotic drug targeting both coagulation Factors XIIa and XIa to reduce bleeding risk in acute cardiovascular settings.
Marche-en-Famenne, Belgium, October 15th, 2019 – Bioxodes, a clinical stage biotech company developing a potential best-in-class antithrombotic agent for acute cardiovascular setting, announces today that the Belgian Federal Agency for Medicines and Healthy Products (FAMHP), together with the designated Ethics Committee, have authorized the initiation of a double blind, placebo controlled, single ascending dose phase I trial with its candidate, Ir-CPI, in healthy male volunteers.
Read the full Press Release here.
Bioxodes raises EUR 7.65 million to cover its clinical Phase I study and to obtain first proofs of efficacy in patients.
Marche-en-Famenne, Belgium, June 2019 – Following a successful preclinical program completion demonstrating the efficacy and safety of its lead compound, Ir‑CPI, Bioxodes SA has completed a EUR 7.65 million capital increase. It was carried out among the current shareholders as well as new investors. A repayable advance of EUR 2.65 million was granted by the Walloon Region which has been actively supportive since the creation of the company. With this capital increase, Bioxodes SA wishes to demonstrate the safety of Ir-CPI in humans (Phase I) but also to obtain first proofs of efficacy in patients.
Bioxodes receives a repayable advance of EUR 500.000 from the Walloon Region
In 2017, Bioxodes received a repayable advance of EUR 550.000 in non-dilutive funding (repayable advance) from the Walloon Region.
Bioxodes raises EUR 7.9 million to bring Ir-CPI to the clinic
Marche-en-Famenne, Belgium, 2015 – Bioxodes SA, the Belgian-based start-up announces that it received EUR 7.9 million to bring Ir-CPI to the clinic. In 2015, Bioxodes closed a EUR 5.2 million Series A financing roud with existing shareholders, new business angels and new Belgian investment fund (SFPI, Sambrinvest) and received a repayable advance of EUR 2.7 million in non-dilutive funding from the Walloon Region (DG06).
Bioxodes’ antithrombotic meets development milestones – Company to launch Series A financing round to bring product to the clinic
Marche-en-Famenne, Belgium, 2015 – Bioxodes SA, the Belgian-based start-up developing pharmaceutical products derived from natural sources, announces that it has successfully brought its lead product, Ir-CPI, trough pre-clinical development confirming its potential as the first in a new class of antithrombotic medicines. The company is now poised to initiate the studies required for clinical entry.
Bioxodes raises EUR 2.6 million to develop antithrombotic peptide derived from tick saliva
Marche-en-Famenne, Belgium, November 2013 - Bioxodes SA, a company developing products derived from natural sources, has completed a EUR 2.6 million first seed funding round with a consortium of business angels and Belgian investment funds. EUR 1.6 million is from the European Regional Development Fund (ERDF) and the Walloon Region in Belgium via the Retech program for Research & Technology.